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Abstract 
Background: In hypoxic tumors, positive feedback between oncogenic KRAS and HIF-1α involves impressive 
metabolic changes correlating with drug resistance and poor prognosis in colorectal cancer. Up to date, 
designed KRAS-targeting molecules do not show clear benefits in patient overall survival (POS) so 
pharmacological modulation of aberrant tricarboxylic acid (TCA) cycle in hypoxic cancer has been proposed as 
a metabolic vulnerability of KRAS-driven tumors. 
Methods: Annexin V-FITC and cell viability assays were carried out in order to verify vitamin C citotoxicity in 
KRAS mutant SW480 and DLD1 as well as in Immortalized Human Colonic Epithelial Cells (HCEC). HIF1a 
expression and activity were determined by western blot and functional analysis assays. HIF1a direct targets 
GLUT1 and PDK1 expression was checked using western blot and qRT-PCR. Inmunohistochemical assays 
were perfomed in tumors derived from murine xenografts in order to validate previous observations in vivo. 
Vitamin C dependent PDH expression and activity modulation were detected by western blot and colorimetric 
activity assays. Acetyl-Coa levels and citrate synthase activity were assessed using colorimetric/fluorometric 
activity assays. Mitochondrial membrane potential (Δψ) and cell ATP levels were assayed using fluorometric 
and luminescent test. 
Results: PDK-1 in KRAS mutant CRC cells and murine xenografts was downregulated using pharmacological 
doses of vitamin C through the proline hydroxylation (Pro402) of the Hypoxia inducible factor-1(HIF-1)α, 
correlating with decreased expression of the glucose transporter 1 (GLUT-1) in both models. Vitamin C 
induced remarkable ATP depletion, rapid mitochondrial Δψ dissipation and diminished pyruvate 
dehydrogenase E1-α phosphorylation at Serine 293, then boosting PDH and citrate synthase activity. 
Conclusion: We report a striking and previously non reported role of vitamin C in the regulation of the 
pyruvate dehydrogenase (PDH) activity, then modulating the TCA cycle and mitochondrial metabolism in KRAS 
mutant colon cancer. Potential impact of vitamin C in the clinical management of anti-EGFR chemoresistant 
colorectal neoplasias should be further considered. 
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Introduction 
Although epidermal growth factor receptor 
(EGFR) inhibitors have been employed to treat 
colorectal cancer (CRC) for decades with great success 
in patients with EGFR mutations, acquired-resistance 
inevitably occurs after long-term exposure, especially 
in those patients harboring mutations in KRAS gene. 
Alterations in TCA cycle are often observed in 









mutation in CRC [1]. As it has been described, KRAS 
and BRAF mutations differentially regulate the 
hypoxic induction of HIF-1α and HIF-2α in colon 
cancer [2]. 
TCA cycle serves as a convergence point in the 
cellular respiration machinery, which integrates 
multiple fuel sources including glucose, glutamine, 
and fatty acids. Although both tumoral and 
non-tumoral cells can catabolize all principal types of 
substrates, they differ in the rate of uptake and 
catabolism of each fuel. While glucose provides the 
main source of pyruvate entering the TCA cycle in 
normal cells, cancer cells often shunt glucose away 
from the TCA cycle for catabolism through anaerobic 
glycolysis, and thus are more dependent on glutamine 
and fatty acids to reload TCA cycle intermediates. 
Healthy normal cells rely on oxidative 
phosphorylation for ATP production. Glycolisis is the 
responsible for the oxidation of glucose into pyruvate 
to produce ATP. Pyruvate is then decarboxylated into 
acetyl-Coa as it enters into the mitochondria, allowing 
to boost the TCA cycle. Cancer cells however, depend 
on aerobic glycolysis for energy production, rewiring 
piruvate to lactate and downregulating catalytic TCA 
cycle. 
Genetic alterations in Krebs cycle enzymes 
and/or aberrant expression of the TCA cycle drivers 
correlate with increased fatty acid β-oxidations and 
epithelial mesenchymal transition (EMT) induction 
[3], which are both characteristics of cancer 
pathogenesis. Alterations in the TCA cycle are, thus, 
of an increasingly attractive interest among the 
oncologists as potential prognostic markers in cancer 
and putative targets for the design of novel antitumor 
molecules. 
Pyruvate dehydrogenase kinase-1 (PDK-1), a key 
mitochondrial enzyme overexpressed in many cancer 
cells, redirects glucose metabolism from oxidative 
phosphorylation toward aerobic glycolysis. The 
pyruvate dehydrogenase complex (PDC) 
decarboxylates pyruvate to acetyl CoA, which is 
further metabolized in the mitochondria [4]. PDKs 
impair this process inactivating the PDC complex 
through phosphorylation of the E1α subunit. 
Recently, aberrant overexpression of PDK-1 has 
been associated to poor prognosis and liver metastasis 
in colorectal cancer [5] and some reports show that 
liver-metastatic breast cancer cells also display high 
expression of PDK-1, strongly pointing out to a key 
role of this enzyme in liver metastasis independently 
of the origin of the primary tumor [6]. 
Interestingly, PDK-1 has been also described to 
promote tumor cell proliferation and migration in 
non-small cell lung cancer (NSCLC) by enhancing the 
Warburg effect [7] and previous works demonstrate 
tight correlation between abnormal cancer cell 
metabolism and KRAS mutation in several neoplasias. 
In 1931, the Nobel Prize in Medicine Otto Warburg 
stated that cancer was primarily caused by altered 
metabolism interfering with energy processing in the 
normal cell. Increased cell glycolytic rates even in the 
presence of oxygen is fully recognized as a hallmark 
in cancer and known as the Warburg effect. 
The KRAS proto-oncogene encodes a ~21 kDa 
small GTPase, which cycles between GTP 
(guanosine-5'-triphosphate)-bound active and GDP 
(Guanosine 5′-diphosphate)-bound inactive states. 
Mutated KRAS is reported in approximately 35%-45% 
of colorectal cancers and >90% of pancreatic ductal 
adenocarcinoma (PDAC) correlating with abnormal 
metabolic rates, enhanced glucose uptake and 
resistance to EGFR-targeted therapies as well as 
preoperative chemoradiotherapy (CRT) [8-10]. 
As it has widely been described, several clinical 
trials have shown that KRAS mutations in cancer 
involve a lack of response to targeted anti-epidermal 
growth factor receptor (EGFR)-based therapies. 
Therefore, anti-EGFR therapies using cetuximab 
and/or panitumumab are now limited to patients 
with KRAS wild-type CRC [11-13]. 
Although several strategies to modulate KRAS 
aberrant activation have been designed, all attempts 
to target KRAS protein have failed in the clinical 
assays and it has been assumed to be invulnerable to 
chemotherapeutic attack. 
It should be possible to design small molecules 
directly binding to GTP-binding site of KRAS then 
blocking its interaction with GTP. However, given the 
extraordinarily high affinity of KRAS for GTP and the 
abundance of GTP in cell cytoplasm (0.5 mmol/L) as 
well as the lack of well-defined hydrophobic pockets 
on the surface of RAS protein, this approach is 
currently considered unfeasible. 
Evidences of the close link between mutant 
KRAS, the pyruvate dehydrogenase complex (PDHC) 
and the Warburg Effect in cancer are rapidly 
increasing. 
In 2017, Trinidad AG et al, published that 
pyruvate dehydrogenase kinase 4, one of the 4 
members of de PDK family, exhibited a novel role in 
the activation of mutant KRAS, regulating cell growth 
in lung and colorectal tumour cells. Moreover, 
depletion of PDHK4 caused disruption of KRAS 
cellular localization and therefore a reduction in 
KRAS activity which, in turn, resulted in reduced 
MAPK signalling [14]. 
Other works have reported that PDK inhibition 
of the pyruvate dehydrogenase complex is critical for 
the aberrant preferential activation of glycolysis, often 
observed in the Warburg metabolism [15]. 





In 1976, Linus Pauling and Ewan Cameron 
performed a pioneering clinical study of the survival 
times of 100 cancer patients who were given ascorbate 
(usually 10 g/day) plus adjuvant chemotheray and 
1000 matched controls, patients who had received the 
same treatment except for the vitamin C. Survival 
times greater than 1 yr after the date of untreatability 
were observed for 22% of the ascorbate-treated 
patients and for 0.4% of the controls [16]. 
In 2015 an original article published in Science 
by Yun J et al., stated that oxidized vitamin C was able 
to kill CRC cells depending on the KRAS mutational 
status [17]. They found that cultured human CRC cells 
harboring KRAS or BRAF mutations were selectively 
killed when exposed to high levels of vitamin C. 
Later, in 2016 we published a scientific work 
partially confirming previous observations of Yun et 
al., but mainly focused on the putative interaction of 
vitamin C in the Warburg metabolism. In this work 
we described a novel antitumoral mechanism of 
vitamin C in KRAS mutant colorectal cancer involving 
the Warburg metabolic disruption through 
downregulation of key metabolic checkpoints in 
KRAS mutant cancer cells and tumors without killing 
human immortalized colonocytes [18]. 
More recently, it has also been described that 
Vitamin C is capable to kill hepatic cell lines and 
BRAF mutated thyroid cancer cells with high efficacy 
[19, 20]. 
Also, an interesting work carried out by Di Tano 
et al, (2020) pointed out to a synergistic effect of 
fasting-simulated diet and vitamin C against KRAS 
mutated cancers suggesting that vitamin C may 
represent a promising low toxicity intervention to be 
tested in randomized clinical trials against colorectal 
cancer [21]. 
We propose that pharmacological targeting of 
tricarboxylic acid (TCA) cycle in hypoxic and hard-to- 
treat neoplasias may constitute a novel approach in 
the treatment and/or chemosensibilization of KRAS 
driven tumors. Data here displayed places vitamin C 
as an unexpected capital inhibitor of tumor 
metabolism in KRAS mutant CRC, regulating the 
expression of PDK-1 and, therefore, the activity of the 
PDHC complex, boosting the conversion of pyruvate 
into Acetyl CoA within the mitochondria. 
Methods 
Cell culture and cell lines 
SW480 and DLD1 cells were cultured in DMEM 
supplemented with 10% Fetal Bovine Serum (FBS) 
(Invitrogen) in a humidified atmosphere containing 
5% CO2 at 37 °C. Cells lines were originally obtained 
from the American Type Culture Collection (ATCC) 
and authenticated using GenePrint® 10 system 
(Promega), which allows co-amplification and 
three-color detection of ten human loci: TH01, TPOX, 
WA, Amelogenin, CSF1PO, D16S539, D7S820, 
D13S317 and D5S818. Short Tandem Repeats profiles 
were sent for comparison against cell line databases 
(ATCC, DSMZ). Last test was done on February 2015. 
SW480 derive from primary tumour and 
lymph-node metastasis and harbors a mutation in 
codon 12 of the RAS proto-oncogene (G12V). 
DLD1 derive from primary tumor and carries the 
heterozygous KRAS G13D mutation. 
Both cell lines neither were exposed to previous 
chemotherapy nor anti-EGFR treatment. Inmortalized 
human colonocytes (HCEC) were provided by Prof. 
Manel Esteller IDIBELL (Barcelona, Spain). 
To mimic hypoxia conditions, hypoxia agent 
NiCl2 was added to the medium in the final 
concentration of 500 µM. MG-132, resuspended on 
DMSO, was used in order to block protein 
degradation by proteasome, it was added to the 
medium in the final concentration of 25 µM (up to a 
maximum of 6 hours) Vitamin C solution stock was 
prepared from L-Ascorbic acid powder diluted in 
Ringer-Lactate Buffer. L-Ascorbic acid, Nickel 
Chloride (NiCl2) were purchased from Sigma. 
MG-132 (462482 MG-132 5MG) was obtained from 
ENZO (Palex Medical, S.A). 
Antibodies 
HIF-1α antibody 1:1000 (abcam reference 
#ab51608), GLUT1 antibody 1:1000 (Merk Millipore 
reference #07-1401), PDK1 antibody 1:1000 (abcam 
reference #ab110025), HIF-1α OH-P402 1:1000 (abcam 
reference #ab72775), Beta-actin antibody 1:10000 (cell 
signaling, Cat. #4967), Pyruvate dehydrogenase 
E1-alpha subunit 1:2000 (abcam reference #ab 
ab110334) and Pyruvate dehydrogenase E1-alpha 
subunit (phospho S293) 1:1000 (abcam reference 
#ab177461) were used for western blot. GLUT1 and 
PDK1 were used for Immunohistochemistry assays. 
Cell viability assays 
HCEC, SW480 and DLD1 were treated with 
pharmacological concentrations of vitamin C (0-5 
mM) for 24 hour. Then, cells were trypsinized and 
fixed with trypan blue solution (Sigma-Aldrich). Cell 
counting was carried out using a TC20TM Automatic 
Cell Counter (Biorad). For time-course treatment 
assay cell lines were treated with 5 mM vitamin C 
during 2, 4, 6, 8, 12 and 24 hours, after treatment cells 
were washed twice with PBS and then cells were 
cultured in DMEM supplemented with 10%. Survival 
percentage of cells was determinated with Cell 
Counting Kit assay (CCK8, Sigma Aldrich #96992). 






HCEC, SW480 and DLD1 were treated with 
vitamin C (5mM) for 24 hours. 3-5 × 105 cells were 
collected by trypsinizing, centrifugation and 
resuspended in 100 μL of PBS. Afterwards, 5 μL of 
annexin V-FITC and 5 μL of propidium iodide were 
added and incubated for 15 min in the dark, then 400 
μL of PBS were added and samples were incubated 
for 45 min at RT in the dark. V-FITC binding was 
analyzed by flow cytometry using a BD FACS Canto 
II device (Becton, Dickinson and Company) (Ex = 488 
nm; Em = 350 nm) using FITC signal detector and PI 
staining by the phycoerythrin emission signal 
detector. 
Western blots 
Protein samples (25 μg protein/lane) were 
resolved by 12% SDS-PAGE and electrotransferred 
onto transfer membranes that were blocked with 5% 
Skim milk () for 1 hour at RT. The blots were 
incubated overnight at 4oC with antibodies of interest 
(mentioned before). After washing four times with 
TBS-T (0.1% Tween-20 in Tris-buffered saline, TBS) 
the blots were incubated with horseradish 
peroxidase-labeled goat anti-mouse or anti-rabbit IgG 
antibodies, then membranes were washed again four 
times with TBS-T. Inmunoblots were visualized using 
an enhancer chemiluminiscence detection kit (ECL 
Prime; GE Healthcare) and imaged using an 
Amershan Imager 600 All western blot images are 
representative of 3 different experiments or biological 
repeats. 
HIF 1α functional analysis 
In order to mimic hypoxia conditions, cells were 
pretreated with NiCl2, ascorbate or both along 12 
hours for SW480 and during 24 hours for DLD1. In 
previous HIF1α measurements, the nuclei were 
isolated using a Nuclear Extraction Kit (abcam). The 
total amount of HIF1α in cell lysates was determined 
by HIF1α transcription factor assay Kit from abcam 
(ab133104) per manufacturer instructions. 
Mitochondrial membrane potential (ΔΨm) 
measurements 
DLD-1 and SW480 cells were cultivated in 
P96-well plate and treated with NiCl2 (500µM), 
ascorbate or both for 2, 4 and 6 hours. ΔΨm 
determination was carried out using an JC-1 - 
Mitochondrial Membrane Potential Assay Kit 
(abcam). 
ATP measurements 
DLD-1 and SW480 cells were cultivated in 
P96-well plate and treated with NiCl2 (500 µM), 
ascorbate or both for 2 and 6 hours. ATP 
determination was carried out using an ATP 
Luminiscent assay from abcam (abcam). 
RT-PCRq 
Total RNA was isolated from SW480 and DLD1 
cells using an RNeasy Mini Kit (Qiagen) following the 
manufacturers protocol. mRNA quality and quantity 
was spectrophotometrically assessed using a 
NanoDrop 200 UV/Vis spectrophotometer. cDNA 
was synthesized from total mRNA using the 
Advantage RT-for-PCR kit (Clonetech Laboratories) 
following the manufacturers protocol. PCR analysis of 
target sequences were generated using the Advantage 
cDNA kit (Clonetech Laboratories) with the following 
PCR primers; GLUT1: 50 – TCATCAACCGCAACGA 
GGAG – 30(Forward), 50 – CAAAGATGGC- 
CACGATGCTC – 30 (Reverse); BNIP3: 50 – TGGACG 
GAGTAGCTC- CAAGA – 30 (Forward), 50 – 
TCATGACGCTCGTGTTCCTC – 30 (Reverse); bactin: 
50 – GCTGCTCGTCGACAACGGCTC – 30 
(Forward), 50 – CAAACATGATCTGGGTCATCTT 
CTC – 30 (Reverse). PCR condition: 95 _C 1 min; 25 
cycles of 95 _C 30 s, 57 _C 1 min, 72 _C 2 min; 72 _C 5 
min. PCR products were separated on 1% agarose gel 
containing GelRedTM nucleic acid stain (Biotium) 
and visualized by UV using a PhotoDyne Imaging 
system (PhotoDyne Technologies). cDNA and PCR 
products were generated using MJ Mini Personal 
Thermal Cycler (Biorad). 
Immunohistochemistry assays 
The paraffin embedded sections were cleared 
and the sections were incubated with 0.1% Pronase 
(Roche #165 921) in 0.1% CaCl2 pH 7.8. at 37C for 10 
minutes. They were blocked with 3% H2O2 in TBS for 
10 mins., washed then blocked with Dako Biotin 
Blocking System (Dako X0590). After washing, they 
were further blocked with 10% Normal Rabbit Serum 
for 10 mins at room temperature (RT) and incubated 
firstly with PDK1 (Abcam, ab110025) dilution 1:50, 
and GLUT-1 (Abcam, ab652) dilution 1: 1000 for 1h at 
RT, then with biotinylated Rabbit Anti-Mouse (Dako, 
E-0354) at 1/100 for 30 mins. at RT, and finally with 
Strep-ABC complex (Dako, K-0377) at 1/100 for 30 
mins. at RT. The sections were developed with AEC 
substrate kit (vector lab, SK-4200) at RT for 20 mins., 
counterstained with haematoxylin and mounted with 
DAKO aqueous mount (Dako, 003181). 
Measurements of PDH, citrate synthase 
activity and acetyl-CoA levels 
PDH activity was determined using the PDH 
Activity Colorimetric Assay Kit (Biovision, Mountain 
View, CA) according to the manufacturer’s 
instructions. Briefly 3×106 cells were seeded and 





pretreated with NiCl2 (500 μM), ascorbate or 
combination along 8 hours for SW480 and during 24h 
for DLD1. Cells were lysed in PDH buffer and PDH 
activity was measured by the kinetic reduction of 
NAD to NADH, which resulted in a colorimetric (450 
nm) product proportional to the enzymatic activity 
present. Citrate synthase activity was quantified using 
a Citrate Synthase (CS) Activity Colorimetric Assay 
Kit (BioVision, Milpitas, CA), according to the 
manufacturers’ instructions at the same conditions. 
Acetyl-CoA levels were measured by Pico-Probe 
Acetyl-CoA Fluorometric Assay kit (BioVision, 
Milpitas, CA) according to manufacturer’s 
instructions. All assays were normalized with protein 
concentrations. 
Murine assays 
SW480 KRAS (G12V) cells were used to generate 
xenograft model in female athymic nude mice 
Foxn1nu, 7 weeks old (Harlan Laboratories). 
Suspensions of 2×106 cells were injected 
subcutaneously in control and experimental mice. 
Once the tumor size volume reached 100 mm3, the 
mice were treated with intraperitoneal (i.p) vehicle or 
vitamin C (4gr/Kg) once daily with the same dosing 
schedule (SW480: n = 10) for 15 days. Tumors were 
measured twice weekly in three perpendicular 
dimensions using a vernier caliper and tumor volume 
was calculated using the ellipsoidal formula V (mm3) 
= 1/6 π × length (mm) × width2 (mm2). 
Statistical analysis 
Data are expressed as the mean ± S.E. 
Differences in measured variables were assessed with 
ANOVA test and p value of <0.05 was considered 
significant. Statistical evaluation was performed using 
SPSS 18.0.2 and GraphPad Prism 6. 
Results and Discussion 
Vitamin C selectively kills KRAS mutant CRC 
cell lines without affecting normal colon cells 
We aimed to investigate whether vitamin C 
could have some antitumoral activity in 
chemoresistant CRC in assays carried out using 
SW480 and DLD1 cell lines, displaying KRAS 
mutations and no sensitivity to cetuximab. 
SW480 and DLD1 cancer cells both harboring 
KRAS mutation (G12V and G13D respectively) and 
immortalized human colonocytes (HCEC) (KRAS 
wild type) were exposed to ascorbate for 2h to 
simulate clinical pharmacokinetics, and the effective 
concentration that decreased survival to 50% (EC50) 
was determined. Observed EC50 was ≤ 10 mM for 
both tumor cells lines tested. Remarkably, 
significative cytotoxicity in HCEC cells treated with 5 
mM ascorbate was not detected (Figure 1A-1B). 
Mortality observed for both cancer cell lines was ≥ 
60% just 36 h. after treatment (Figure 1C), although 
DLD1 displayed more resistance to ascorbate. We 
conclude that the effect of vitamin C seems to be, at 
least in part, dependent on the mutational status of 
KRAS as previously stated by Yun J et al. [17]. 
Interestingly, KRAS mutation has been demonstrated 
to drive aberrant changes in the cell metabolic 
homeostasis in colon and pancreatic tumors [22, 23]. 
HIF-1α stability and transcriptional activity are 
both inhibited by vitamin C in KRAS mutant 
CRC 
As it has been previously reported, the hypoxic 
microenvironment of cancer cells results in drug 
resistance. Hypoxia associates with many signaling 
pathways, including PI3K/AKT, MAPK, or NOTCH 
and, interestingly, HIF-1 α protein expression is 
higher in cells displaying KRAS mutation [2]. 
Hypoxia-inducible factor 1 (HIF-1) is a 
heterodimeric protein that consists of two subunits, 
HIF-1α and HIF-1β. HIF-1 activates the transcription 
of many genes encoding for proteins that are involved 
in glucose metabolism, cancer proliferation, 
angiogenesis, metastasis and resistance to apoptosis 
[24]. 
High expression of HIF-1 has been detected in a 
vast number of neoplasias boosting the Warburg 
effect, and aberrant expression has been associated to 
poor prognosis in human colon cancer [25, 26]. 
As we can see (Figure 2A), exposure to 500 μM 
NiCl2 led to an increased and sustained stabilization 
of HIF1α subunit in SW480 and DLD1 cancer cells, an 
effect that vitamin C was able to reverse. In fact, after 
6 and 8 h of exposure to ascorbate, HIF-1α was hardly 
detected in both SW480 and DLD1. In control assays 
displayed in Figure S1 we checked out that NiCl2 
exposure neither affected cell viability nor induced 
apoptosis is a significant manner. 
We also performed assays to check out if HIF-1 
transcriptional activity might also be affected by 
vitamin C. In this experiment, a specific double 
stranded DNA (dsDNA) sequence containing the 
HIF-1α response element (5’-ACGTG-3’) is 
immobilized inside of a 96-well plate. HIF-1α present 
in the cell nuclear extract, binds specifically to the 
HIF-1α response element. The HIF transcription factor 
complex is then detected by addition of a specific 
primary antibody directed against HIF1α and a 
secondary antibody conjugated to HRP is 
consequently added to provide a sensitive 
colorimetric reaction.Both cell lines were treated with 
500 μM NiCl2 and 5mM vitamin C for 6 h. 






Figure 1. Vitamin C selectively kills KRAS mutant colon cancer cells A. Apoptosis-induced by vitamin C in normal human immortalized Colonocytes (HCEC), SW480 
and DLD1 cancer cell lines were annalyzed by Annexin-PI assay. Each cell line (2,5 105 cells) was incubated with vitamin C (10 mM) and PBS for controls for 24 h. Apoptosis in 
each cell line was measured by staining with FITC-conjugated Annexin-V and Propidium Iodide (PI) using a Sigma-Aldrich Apoptosis kit. The populations of cells (annexin-V 
positive/PI negative) and late apoptotic cells (annexin-V positive/PI positive) as a percent of total cells were evaluated. Vitamin C displayed a selective killing effect on SW480 and 
DLD1. One-way ANOVA followed by Dunnett’s post-test for multiple comparisons. *p< 0.05, **p < 0.001, n = 3. B.images show apoptotic activity in KRAS mutant SW480 and 
DLD1 cell lines after vitamin C treatment (10 mM) for 24 h. C. vitamin C treatment at different concentrations were carried out with HCEC and DLD1 and SW480 cancer lines. 
All cell lines were exposed to ascorbate at 1, 3 and 5mM, for 24 h. Then, cells were tripsinized and fixed with trypan blue solution (Sigma-Aldrich). Cell counting was carried out 
using a neubauer chamber (SigmaAldrich) One-way ANOVA followed by Dunnett’s posttest for multiple comparisons < 0.05, **p < 0.001, n = 3. D. HCEC, SW480 and DLD1 
cells were treated with 5Mm and 6Mm vitamin C respectively for 4,6, 12 and 24 h. Then, cells were tripsinized and fixed with trypan blue solution (SigmaAldrich). Cell counting 
was carried out using a neubauer chamber (SigmaAldrich) One-way ANOVA followed by Dunnett’s posttest for multiple comparisons. *p < 0.05, **p < 0.001, n = 3. 
 
Figure 2. Vitamin C reduces HIF1a activity and stability. A. HIF1a expression in KRAS mutant cell lines SW480 and DLD1 treated with vitamin C (5 Mm; 6 mM) and 
NiCl2 (0.5 Mm) for 6, 8, 12 and 24 h. NiCl2 upregulates HIF1a expression mimicking tumor conditions which is downreguated when vitamin C is added. B. HIF1a activity in 
KRAS mutant cell lines SW480 and DLD1 treated with vitamin C (5 Mm; 6 mM) and NiCl2 (0.5 Mm). Vitamin C is able to downregulate the HIF1 increased transcriptional activity 
showed when cells are treated with Nicl2. C. Hidroxilated HIF1a expression in KRAS mutant cell lines SW480 and DLD1 treated with vitamin C (5 mM; 6 mM) and MG132 for 
1, 3 and 6 h. Vitamin C induces hidroxilated HIF1a accumulation when proteasome is blocked at 6h. 
 
As it is displayed in Figure 2B, addition of NiCl2 
led to a huge increase of HIF-1α binding to the above 
mentioned HIF-1α response element. Vitamin C 
treatment led to a massive inhibition of HIF1α 





transcriptional activity, similar to that observed for 
the negative control provided in the assay. 
Previous works have reported that the Factor 
Inhibiting HIF-1 (FIH-1) is involved in the cellular 
response to hypoxia physically interacting with HIF-1, 
blocking its transcriptional activity under normoxic 
conditions [27]. The hypothesis that the inhibition of 
the transcriptional activity of HIF1 could be mediated 
by a vitamin C-dependent increase of FIH1 expression 
does not sound too far-fetched. 
HIF-1α possesses an oxygen dependent 
degradation domain, containing two prolines in 
positions 402 and 564 that are hydroxylated in 
presence high O2 pressure. After hydroxylation, 
HIF1α binds to the pVHL-ubiquitin ligase complex 
and it is directed to proteasome for degradation [28]. 
NiCl2 is added to the cell cultures to mimic hypoxia 
conditions and avoiding hydroxylation of both 
prolines. We wondered whether vitamin C might 
exert its activity on HIF-1α reverting NiCl2 
hydroxylation protective effect. 
For this purpose, we treated both cell lines with 
25 μM of MG-132 (a proteasome inhibitor) up to a 
maximum of 6 hours. Again, 500 μM NiCl2 was also 
added to simulate hypoxia conditions. Then, cells 
were treated with 5 mM ascorbate for 1, 3 and 6 h. 
In SW480 cells, a time dependent accumulation 
of HIF-1α was observed. Remarkably, vitamin C 
induced an observable accumulation of HIF-1 α 
(hydroxy P402) after 6 h of treatment (Figure 2C). So, 
Vitamin C leads to an increased proteasome 
degradation of HIF-1 α in cancer cells. Once again 
control assays were performed in order to ensure that 
MG132 did not affect cell viability (Figure S2). 
Curiously, the effects observed in DLD1 were 
slightly different. HIF-1α did not experiment any kind 
of alteration, and it remained equal at 1, 3 and 6 h. 
However, hydroxylated HIF-1 α (P402) displayed a 
massive increase after 6 h treatment with vitamin C. 
In spite of the observed differences in HIF-1α 
accumulation, we can conclude that vitamin C is 
somehow able to counteract the protective effect of 
NiCl2 on HIF-1 α at proline 402. 
Vitamin C induces PDK-1 inhibition leading to 
increased mitochondrial PDH activity 
HIF-1-dependent expression of pyruvate 
dehydrogenase kinase is a metabolic switch which is 
needed for cellular adaptation to hypoxia [29]. 
As it has been previously described, 
overexpression of PDK-1 in CRC is associated to poor 
prognosis and liver metastasis [4]. Moreover, Chin et 
al., reported that PDK1 silencing in SW480 and 
HCT116 CRC cells tightly correlates with both 
decreased viability and proliferation [5] enhancing the 
role of PDK1 in KRAS mutant neoplasias. 
High expression of PDK-1 leads to enhanced 
phosphorylation of the pyruvate dehydrogenase 
complex and reduced TCA activity. Since we have 
previously reported that vitamin C uncouples the 
Warburg effect [18], we performed assays to check out 
whether expression and/or activity of PDK-1 might 
be affected by vitamin C. 
Western blot analysis was performed using both 
DLD1 and SW480 KRAS mutant cancer cell lines. As 
described, in order to mimic hypoxic conditions cells 
were treated with 500μM NiCl2 in order to stabilize 
HIF-1 and enhance the Warburg effect [30]. 
As it can be observed (Figure 3A), NiCl2 
treatment slightly increased PDK-1 expression 
treatment in DLD1 cells after 6 hours treatment, and 
Vitamin C (5 mM) strongly inhibited PDK-1 protein 
expression in both, DLD1 and SW480 CRC cell lines, 
although this effect was more remarkable in SW480 
cell line. 
An interesting study carried out by Luo F., et al 
in 2019, reported that not only PDK1 but also 
Hexokinase II (HKII) that catalyzes the first 
irreversible step of glycolysis and is often 
overexpressed in tumor cells, is also able to promote 
the Warburg effect by phosphorylating alpha subunit 
of pyruvate dehydrogenase at Serine 293 [31]. 
Therefore we wanted to test if the observed vitamin 
C-dependent PDK1 inhibition also correlated with a 
reduction in pyruvate dehydrogenase E1-α 
phosphorylation at Serine 293. 
Western blot analysis clearly showed that 
pyruvate dehydrogenase E1-α phosphorylation at 
Serine 293 was notably reduced after vitamin C 
treatment. 
Interestingly, Vitamin C treatment did not lead 
to changes in the expression of pyruvate 
dehydrogenase in both SW480 DLD1 cancer cells, 
strongly suggesting that diminished pyruvate 
dehydrogenase E1-α phosphorylation was driven by 
the previously observed effect of vitamin C on PDK-1 
expression (Figure 3A). 
However, these results arised an intriguing 
query that would call for further research: might also 
vitamin C treatment affect the expression of 
Hexokinase II in KRAS mutant CRC cells? 
The glucose transporter1 (GLUT-1) is another 
important target of HIF-1, also playing a pivotal role 
in the Warburg effect. Overexpression of GLUT-1 is 
often observed in cancer tightly correlating with 
enhanced cell glycolytic rates and therefore, some 
interesting attempts have been already carried out in 
order to target GLUT1 in cancer [32, 33]. 






Figure 3. Vitamin C interferes with PDK1-mediated phosphorylation of PDH. A GLUT1, PDK1, p-PDH (S293) and PDH expression in KRAS mutant SW480 and 
DLD1 cell lines treated with vitamin C (5 Mm; 6 mM) and NiCl2 (0.5 Mm) for 6 and 24 h. Beta-actin was employed as protein loading control. NiCL2 upregulates PDK1, GLUT1 
expression simulating hypoxic tumor conditions while vitamin C treatment reduces GLUT1, PDK1 and p-PDH expression B. qPCR analysis of Glut1 and Pdk1 in KRAS mutant 
SW480 and DLD1 cell lines treated with vitamin C (5 Mm; 6 mM) and NiCl2 (0.5 mM) for 6 and 24 h. Vitamin C downregulates the expression of Glut1 and Pdk1 at mRNA level. 
C.immunohistochemistry assays in colon cancer patient derived xenografts (PDX) show increased PDK1 expression in Kras mutant patients, n=3. D. immunohistochemistry 
assays in SW480 derived tumors shows in vivo downregulation of GLUT1 and PDK1 in vitamin C-treated tumors. Suspensions of 2×106 cells were injected subcutaneously in 
control and experimental mice Animals were treated (i.p) with vehicle or vitamin C (4 gr/kg body weight) for 15 days once daily. Umpaired t-test with Welchs correction *p < 
0.05, **p < 0.001, n = 3. E. PDH activity in colon cancer SW480 and DLD1 cell lines treated with vitamin C (5 mM; 6 mM) alone or in combination with NiCl2(0.5 mM). Vitamin 
C rescues the inactivation produced by NiCl2 treatment and is able to activate PDH activity when used alone. One-way ANOVA followed by Dunnett’s posttest for multiple 
comparisons. *p < 0.05, ***p < 0.001, n = 3. F. Acetyl-CoA detection in KRAS mutant SW480 and DLD1 cell lines when treated with NiCl2 (0.5 Mm) alone or in combination 
with vitamin C (5 mM; 6 mM). Vitamin C induces acetyl-CoA accumulation One-way ANOVA followed by Dunnett’s posttest for multiple comparisons. *p < 0.05, ***p < 0.001, 
n = 3. G. Ctrate synyhase (CS) activity in colon cancer SW480 and DLD1 cell lines treated with vitamin C (5 mM; 6 mM) alone or in combination with NiCl2(0.5 mM). Vitamin 
C rescues CS inactivation in hypoxic conditions. One-way ANOVA followed by Dunnett’s posttest for multiple comparisons. *p < 0.05, n = 3. 





Our results show that GLUT1 expression is 
notably increased in NICL2 hypoxic mimicked 
conditions, but protein presence was also drastically 
decreased in both cell lines after 6 hour of 5mM 
vitamin C treatment (Figure 3A). 
We wondered whether vitamin C might also 
affect Hif-1-dependent expression of GLUT-1 and 
PDK-1. As it is shown (Figure 3B), Real-Time 
RT-qPCR analysis displayed enhanced mRNA 
expression of GLUT-1 and PDK1 in response to NiCl2 
but, once again, a notable effect of vitamin C on the 
cell transcriptional activity was observed. PDK-1 and 
GLUT-1 mRNA were differentially downregulated by 
vitamin C even in presence of NiCL2. 
In SW480 cells, GLUT-1 mRNA was already 
significantly downregulated after 6h of vitamin C 
exposure. However, effect of vitamin C on PDK-1 
mRNA expression only could be detected after 12 h of 
treatment. 
Interestingly, a significant effect of vitamin C on 
PDK-1 and GLUT-1 transcriptional mRNA in DLD1 
cells only could be observed after 12 h of vitamin C 
treatment. 
As it was stated above, overexpression of PDK-1 
has already been described in CRC [4] and we 
performed immunohistochemical analysis of PDK1 
expression in a number of KRAS wild type (n=3) and 
KRAS mutant (G12V) (n=3) tumor biopsies in order to 
check whether we could detect variability in PDK-1 
expression. To our surprise, important differences 
were observed and remarkably higher presence of 
PDK-1 was observed in the KRAS mutant samples 
(Figure 3C) suggesting a synergic effect of KRAS 
mutation and HIF-1 on PDK-1 expression. This 
interesting result shows a positive correlation 
between KRAS mutation and PDK1 expression. 
In order to check whether vitamin C might 
modulate in vivo tumoral expression of both HIF-1 
targets, PDK-1 and GLUT-1, we performed xenograft 
assays using athymic nude mice Foxn1nu, 7 weeks old 
(n=10) to observe the putative effect of vitamin C on 
GLUT1 and PDK1 expression. Tumors from SW480 
KRAS (G12V) cells were generated and then mice 
were treated with vehicle or vitamin C (4 gr/kg body 
weight) for 15 days once daily. 
Surprisingly, not only the expression of GLUT-1 
but also PDK-1 was heavily reduced in tumors 
extracted from animals treated with vitamin C, 
therefore supporting our previous observations with 
SW480 and DLD1 cell lines (Figure 3D). 
PDK-1 and GLUT-1 expression in cancer has 
previously been associated to an increased 
stabilization of HIF1α [34, 35], so these results clearly 
show that vitamin C is interfering with the expression 
of enzymes that play a pivotal role in the tumoral 
metabolic shift. 
As it has been reported, alterations in the TCA 
cycle are often observed in hypoxic CRC tumors 
correlating with HIF-1 expression and KRAS 
mutation, but we observed that vitamin C inhibits 
(both HIF-1 targets) GLUT-1 and mitochondrial 
PDK-1 expression in DLD-1 and SW480 CRC cell 
lines. On the contrary, the overall PDH expression 
was not affected by vitamin C in both cell lines tested, 
but we clearly observed modifications in its 
phosphorylation state, associated with activity, 
(Figure 3A). 
The overall of these data upraise a provocative 
question: may vitamin C enhance mitochondrial PDH 
activity, then boosting pyruvate decarboxylation and 
conversion into acetyl-Coa? 
We decided to carry out assays to answer this 
puzzling question: 
The mitochondrial PDH activity and pyruvate 
decarboxylation are associated to a measurable 
reduction of NAD to NADH. So, using DLD-1 and 
SW480 cell extracts, we performed experiments to 
check putative vitamin C-dependent variations on 
PDH activity in presence and absence of 500 µM 
NiCl2. Results are depicted in Figure 3E. 
In normoxic conditions and absence of NICl2, 
vitamin C enhanced PDH activity in a significant 
manner. 
As espected, NICL2 hypoxic conditions strongly 
inhibited PDH activity in both KRAS mutant cancer 
cell lines when compared to the control. However, 
vitamin C enhanced PDH activity even in a higher 
percentage than that observed for normoxic 
conditions. 
These striking results point out to a novel role of 
vitamin C refueling the altered mitochondrial TCA 
cycle with acetyl-Coa and then activating citrate 
synthase activity in KRAS mutant CRC as depicted in 
Figures 3F and 3G. 
These data strongly suggest that if mitochondrial 
pyruvate decarboxilation and conversion to 
acetyl-CoA is enhanced by vitamin C, lactate 
dehydrogenase (LDH) activity and cytoplasmic 
catalysis of pyruvate to lactate might be inhibited in 
the same way. Although these promising results point 
out to an underrated role of vitamin C in the 
metabolic modulation of cancer cells, some authors 
have reported that there are some other enzymes of 
the TCA cycle that show deficient activity or altered 
expression. 
For example, the α-KG dehydrogenase (OGDH) 
that catalyses the conversion of α-ketoglutarate to 
succinyl-CoA is downregulated in colorectal cancer as 
the result of promoter hypermethylation [36]. 





Isocitrate dehydrogenases (IDHs) are enzymes 
that catalyze the oxidative decarboxylation of 
isocitrate. Although rare, mutations of IDH1 and 
IDH2 members have also been observed in colorectal 
tumors [37]. The aberrant functioning of the TCA 
cycle in colorectal cancer is due to various alterations 
in enzymes involved in the cycle itself and, probably, 
other mechanisms yet to be discovered. Therefore, the 
real potential of vitamin C to modulate the 
metabolism of tumor cells requires further 
investigation. 
Vitamin C inhibits ATP generation in SW480 
and DLD1 and dissipates the mitochondrial 
membrane potential (ΔΨm) in SW480 cells 
PDK-1 and the pyruvate dehydrogenase 
complex exert their function inside the mitochondria. 
Vitamin C is a water soluble vitamin taken up 
directly by the cells as l-ascorbic acid (AA) via high 
affinity/low capacity Na+-dependent transporters 1 
and 2 (SVCT1 and 2). Cells also intake the vitamin as 
dehydroascorbic acid (DHA) through hexose 
transporters, an event followed by the rapid 
intracellular reduction back to AA [38-40]. Vitamin C 
is then capable to enter the mitochondria via SVCT2 
transporter. 
Mitochondria are double membrane-enveloped 
organelles that play a key role in cellular metabolism, 
redox signaling, calcium homeostasis, and cell fates. 
 
 
Figure 4. Vitamin C reduces ATP production and dissipates 
mitochondrial potential. A. Mitochondrial membrane potential assay in KRAS 
mutant DLD1 and SW480 cells treated with vitamin C (5 Mm; 6 mM) and NiCl2 (0.5 
Mm) for 2 and 6 h. Vitamin C reduces mitochondrial membrane potential in SW480 
cell line. B. ATP detection assay in SW480 and DLD1 treated with vitamin C (5 Mm; 
6 mM) and NiCl2 (0.5 Mm) for 2, 4 and 6 h. Vitamin C heavily reduces ATP 
production in the cells. One-way ANOVA followed by Dunnett’s posttest for 
multiple comparisons. *p < 0.05, ***p < 0.001, n = 3. 
In healthy cells, mitochondria are the main ATP 
generators, but in many cancer cells, mitochondria do 
not work properly and energy metabolism shifts from 
oxidative phosphorylation to active glycolysis, 
accompanied by an increase in reactive oxygen 
species generation (ROS) and remarkable increased 
transmembrane potential (ΔΨm) [41]. 
In this context, some authors have proposed that 
mitochondrial pyruvate dehydrogenase kinase (PDK) 
inhibitors are capable to shift metabolism from 
glycolysis to glucose oxidation, decreasing ΔΨm in 
cancer, but not normal, cells [42]. 
Our previous data strongly pointed out to 
modulating activities of vitamin C inside the 
mitochondria, and observed vitamin C-dependent 
PDK-1 inhibition led us to design assays in order to 
verify whether vitamin C might also induce changes 
in the membrane potential in CRC cancer cells. 
As it is shown in Figure 4A, mediated-NiCl2 
hypoxic conditions induced an impontant increase of 
the mitochondrial transmembrane potential in SW480 
cells after 2 and 6 h treatment. Addition of 100 uM of 
the proton ionophore FCCP (carbonylcyanide 
p-trifluoromethoxyphenylhydrazone) almost 
abolished ΔΨm. 
Surprisingly, Vitamin C induced a progressive 
depolarization of the mitochondrial ΔΨ and after 6 h 
of exposure; it was almost completely disrupted in a 
similar way of FCCP. 
Interestingly, different results were obtained for 
DLD1 cells. In this case, NiCl2 hypoxic conditions did 
not lead to a significant increase of the mitochondrial 
transmembrane potential (ΔΨm) and Vitamin C was 
not able to abolish it after 2 and 6 h treatment. 
Neither PDK-1 expression nor PDH 
phosphorylation were observed in DLD-1 cells after 6 
h of vitamin C treatment (Figure 3A), but they were 
both inhibited after 24 h exposure to 5 mM vitamin C. 
These observations support the increased resistance of 
DLD-1 cells to vitamin C depicted in Figure 1D. 
A possible explanation for the differential 
activity of vitamin C on SW480 and DLD1 
transmembrane potential may rely on the reported 
differences in the aminoacid sequence of the 
mitochondrial SVCT2 transporter. 
As we previously stated, Vitamin C is taken into 
the mitochondria in cotransport with Na+ via the high 
affinity/low capacity Na+-dependent transporter 
SVCT2. An interesting work by Mouradov et al in 
2014, showed that SVCT2 expressed in DLD1 CRC 
cells display an aminoacid change in position 264 
(E264K). Glutamate (or Glutamic acid) is a negatively 
charged polar aminoacid and it is substituted by a 
positive Lysine in DLD-1 cells [43]. This aminoacid 
substitution implies changes in the isoelectric point 





(IP) of SVCT2 that may affect to the kinetics and 
SVCT2 transport skills. 
Interestingly, vitamin C was able to disrupt ATP 
generation in SW480 and DLD1, although different 
kinetic was observed for both cell lines (Figure 4B). 
Strong inhibition of ATP generation was 
observed in SW480 in normoxic and hypoxic 
conditions just after 2 h exposure to 5 mM vitamin C. 
However, in DLD1 cells we only could report 
significant inhibition of ATP after 6h treatment of 
vitamin C treatment, again supporting our previous 
observations. 
Conclusion 
We hereby present compelling data showing a 
novel and unexpected role of vitamin C in the 
modulation of altered mitochondrial metabolism in 
KRAS-mutant CRC. In summary, vitamin C induces 
HIF1α proteasomal degradation, consequently 
downregulating the expression of its direct targets 
PDK1 and GLUT1. Downregulated PDK1 correlates 
with reduced phosphorylation of PDH, implying an 
elevated enzyme activity. Increased PDH activity 
involves, then, enhanced pyruvate decarboxylation 
into acetyl-Coa, strongly pointing out to an important 
role of vitamin C rewiring the tumor reprogrammed 
tricarboxylic acid (TCA) cycle. The role of vitamin C 
in the clinical management of hypoxic KRAS mutant 
colon cancer and importance of normal plasmatic 
vitamin C (AA) levels in those patients should be 
reassessed. 
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